JEWJITSU PEPTIDES Research Roundup: eCIRP in Stroke, BSN‑37 and circRNA, GLP‑1 Persistence

The first study used a transient middle cerebral artery occlusion (tMCAO) model to examine extracellular cold‑inducible RNA‑binding protein (eCIRP) in ischemic stroke. The authors report that eCIRP is released into the cerebrospinal fluid after tMCAO and that microglial expression of the efferocytic receptor MerTK decreased in these mice. They describe a signaling cascade in which eCIRP activates TLR4, inducing microRNA‑155 (miR‑155) that suppresses the pro‑efferocytic transcription factor MafB; this suppression is reported to downregulate MerTK and downstream cytoskeletal regulators, impairing microglial efferocytosis. The paper also reports that genetic CIRP deficiency was associated with improved MerTK expression and microglial efferocytosis and with changes in infarction, inflammation, neurological deficit, and survival measures in the acute stroke model.

That same stroke report evaluated pharmacologic blockade of the eCIRP–TLR4 interaction using a small peptide called C23. According to the abstract, C23 attenuated induction of miR‑155, restored MerTK expression, rescued microglial efferocytosis, and improved outcome measures in the tMCAO mice. The study presents a proposed molecular pathway linking an extracellular inflammatory mediator to reduced neuroprotective clearance by microglia, and it frames targeting eCIRP as a possible approach to promote functional recovery after stroke. The work, as reported, is preclinical and uses an experimental mouse model; implications for human disease are not established in the abstract.

Methodological and translational limits are noted in the report itself: findings derive from a mouse tMCAO model and from interventions tested in that context. The abstract highlights molecular associations and effects of genetic deficiency or peptide blockade on measured outcomes in the model, but it does not provide direct evidence in humans or detailed clinical data. Readers should therefore interpret the mechanistic chain and reported outcome changes as model‑based results that would require further validation in additional preclinical settings and, ultimately, clinical research before clinical relevance can be determined.